IDH2 and non-small cell lung carcinoma: In the present study, analysis of nearly 18,000 NSCLC specimens revealed a 2.01% rate of IDH mutations in Chinese patients, which was significantly higher than that in European and American populations (1.1%) reported in the TCGA and may define a subset of Chinese NSCLC patients.